MetaCap

Kiniksa Pharmaceuticals International (KNSA) vs Protagonist Therapeutics (PTGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiniksa Pharmaceuticals International (KNSA) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 125.8% versus a gain of 42.2%. Over five years, KNSA leads with a +706.0% price change compared with +265.0% for PTGX. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.38 billion), about 1.1 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs -89.4%).

On valuation, Kiniksa Pharmaceuticals International trades at a lower forward P/E (45.9x vs 348.8x for Protagonist Therapeutics). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -282.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KNSA+125.82%PTGX+42.15%
+145%+64%-16%
Nov 21, 20251 yearNov 20, 2026
KNSA+669.63%PTGX+246.56%
+728%+305%-118%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KNSA versus PTGX key metrics
MetricKNSAPTGX
Share price$93.90$121.40
Market cap$7.38B$7.92B
1-day change+0.38%-2.11%
YTD return+127.62%+39.00%
1-year return+125.82%+42.15%
5-year return+705.97%+265.00%
P/E ratio (TTM)71.1325.67
Forward P/E45.91348.79
EPS (TTM)$1.32$4.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$677.56M$46.02M
Revenue growth (YoY)+60.09%-89.41%
Net income (latest FY)$59.01M$-130.15M
Gross margin88.54%—
Operating margin11.40%-343.63%
Net margin8.71%-282.83%
52-week high$99.31$160.81
52-week low$37.02$77.00
Distance from 52-week high-5.45%-24.51%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+18.82%+50.21%
Average volume664.53K668.45K
Shares outstanding48.84M65.27M
Employees366149
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KNSA has outperformed PTGX by 83.7 percentage points over the past year.
  • Kiniksa Pharmaceuticals International trades at a higher earnings multiple (71.1x vs 25.7x trailing P/E).
  • Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
  • Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs -89.41%).

About Kiniksa Pharmaceuticals International

KNSA stock →

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees

About Protagonist Therapeutics

PTGX stock →

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees

KNSA vs PTGX FAQ

Which is bigger, Kiniksa Pharmaceuticals International or Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.38B for Kiniksa Pharmaceuticals International (KNSA).

Which stock has performed better over the past year, KNSA or PTGX?

KNSA returned +125.82% over the past 12 months, compared with +42.15% for PTGX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, KNSA or PTGX?

PTGX has the lower trailing P/E at 25.7, versus 71.1 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Kiniksa Pharmaceuticals International and Protagonist Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons